Streamlining Pharmacist-Led Hyperglycemia Management in HR+ Breast Cancer: Overcoming PI3K/AKT Inhibitor Challenges

Stream link: https://event.arraylive.com/ap...

This satellite symposium will be broadcast live from the 2025 Community Oncology Conference in Lake Buena Vista, Florida. If you would like to attend in-person, please click here to register.

Program Description

Hormone receptor-positive (HR+) breast cancer accounts for 80% of new breast cancer cases, and treatment often involves endocrine therapy and a CDK 4/6 inhibitor. However, resistance to endocrine-based therapy remains a challenge. The PI3K/AKT/mTOR pathway is a key target for this subtype, leading to a rise in new inhibitors with new adverse effects, such as hyperglycemia. Data from clinical trials and real-world studies will be presented to illustrate the incidence and clinical presentation of hyperglycemia with these therapies. As there is limited guidance on first-line therapies, management of hyperglycemia in patients with HR+ breast cancer receiving PI3K and AKT inhibitors remains challenging. Expert faculty will discuss strategies for hyperglycemia prevention, lifestyle interventions, and factors informing the selection of appropriate anti-hyperglycemic agents. The importance of interdisciplinary collaboration and the role of clinical oncology pharmacists in preventing, identifying, and managing hyperglycemia associated with these therapies will be emphasized throughout this session.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 29, 2025
Expiration date: June 29, 2025

Time to complete activity: 0.75 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the incidence, severity, and clinical impact of hyperglycemia associated with different PI3K and AKT inhibitors, recognizing how these adverse effects influence treatment decisions
• Adapt evidence-based strategies for prevention or mitigation of hyperglycemia caused by PI3K and AKT inhibitors into breast cancer treatment plans
• Explore pharmacologic and nonpharmacologic interventions for managing hyperglycemia in patients with breast cancer receiving PI3K or AKT inhibitors, aiming to maximize treatment effectiveness

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-25-014-L01-P. The activity is available for CE credit through June 29, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Cassandra L. Perkey, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Pharmacosmos, Janssen, Assertio (Advisory Boards)

Christin Molnar, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: AbbVie, Genmab

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms